Hexamethylmelamine has been recognized as having useful single-agent activity for the treatment of ovarian cancer for the past 25 years, with some patients surviving disease-free for periods in excess of 12 years. Data from recently analysed and mature trials demonstrate that the addition of hexamethylmelamine to first-line combination chemotherapy results in significant improvements in survival compared to what is achieved with regimens of cisplatin and cyclophosphamide with or without doxorubicin.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0305-7372(91)90026-v | DOI Listing |
Publication Analysis
Top Keywords
ovarian cancer
8
role hexamethylmelamine
4
hexamethylmelamine management
4
management ovarian
4
cancer hexamethylmelamine
4
hexamethylmelamine recognized
4
recognized single-agent
4
single-agent activity
4
activity treatment
4
treatment ovarian
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!